HUP0300857A3 - Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists - Google Patents

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Info

Publication number
HUP0300857A3
HUP0300857A3 HU0300857A HUP0300857A HUP0300857A3 HU P0300857 A3 HUP0300857 A3 HU P0300857A3 HU 0300857 A HU0300857 A HU 0300857A HU P0300857 A HUP0300857 A HU P0300857A HU P0300857 A3 HUP0300857 A3 HU P0300857A3
Authority
HU
Hungary
Prior art keywords
oxazolyl
acid derivatives
ppar agonists
arylpropionic acid
arylpropionic
Prior art date
Application number
HU0300857A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0300857A2 publication Critical patent/HUP0300857A2/hu
Publication of HUP0300857A3 publication Critical patent/HUP0300857A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
HU0300857A 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists HUP0300857A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
HUP0300857A2 HUP0300857A2 (hu) 2003-10-28
HUP0300857A3 true HUP0300857A3 (en) 2007-03-28

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300857A HUP0300857A3 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Country Status (26)

Country Link
US (2) US6930120B2 (enExample)
EP (1) EP1313716B1 (enExample)
JP (1) JP2004506721A (enExample)
KR (1) KR20030027054A (enExample)
CN (1) CN1471517A (enExample)
AT (1) ATE361283T1 (enExample)
AU (1) AU2001284659A1 (enExample)
BR (1) BR0113409A (enExample)
CA (1) CA2418104A1 (enExample)
CY (1) CY1107679T1 (enExample)
CZ (1) CZ2003482A3 (enExample)
DE (1) DE60128239T2 (enExample)
DK (1) DK1313716T3 (enExample)
EA (1) EA200300286A1 (enExample)
EC (1) ECSP034504A (enExample)
ES (1) ES2286137T3 (enExample)
HU (1) HUP0300857A3 (enExample)
IL (1) IL154110A0 (enExample)
MX (1) MXPA03001558A (enExample)
NO (1) NO20030729L (enExample)
NZ (1) NZ523804A (enExample)
PL (1) PL360744A1 (enExample)
PT (1) PT1313716E (enExample)
SK (1) SK1872003A3 (enExample)
WO (1) WO2002016331A1 (enExample)
ZA (1) ZA200300570B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018355A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
JP2004506722A (ja) * 2000-08-23 2004-03-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体の調節方法
DK1392295T3 (da) 2001-05-15 2006-10-02 Hoffmann La Roche Carboxylsyre-substituerede oxazol-derivater til anvendelse som PPAR-alpha og -gamma-aktivatorer i behandlingen af diabetes
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
PL374818A1 (en) 2002-07-03 2005-10-31 F.Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
EP1537091B1 (en) 2002-08-30 2010-10-06 F. Hoffmann-La Roche AG Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
BR0314261A (pt) 2002-09-12 2005-07-26 Hoffmann La Roche Compostos, processo de preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de um composto, método para tratamento e/ou profilaxia de enfermidades e utilização e/ou método de tratamento
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
KR100699614B1 (ko) * 2002-11-08 2007-03-23 에프. 호프만-라 로슈 아게 퍼옥시좀 증식자 활성화된 수용체 작용제로서의 치환된4-알콕시옥사졸 유도체
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
US20070293423A1 (en) * 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
CA2245529A1 (en) 1996-02-02 1997-08-07 Soumya P. Sahoo Antidiabetic agents
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR20000068151A (ko) * 1996-08-19 2000-11-25 미즈노 마사루 프로피온산 유도체 및 그의 용도
AU3275999A (en) 1998-03-10 1999-09-27 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
JP2004506722A (ja) 2000-08-23 2004-03-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体の調節方法
WO2002018355A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
NO20030729D0 (no) 2003-02-14
ZA200300570B (en) 2004-04-21
DK1313716T3 (da) 2007-08-27
US20040097590A1 (en) 2004-05-20
EA200300286A1 (ru) 2003-08-28
US20050245584A1 (en) 2005-11-03
NZ523804A (en) 2004-09-24
NO20030729L (no) 2003-04-02
WO2002016331A1 (en) 2002-02-28
AU2001284659A1 (en) 2002-03-04
MXPA03001558A (es) 2003-06-06
JP2004506721A (ja) 2004-03-04
ECSP034504A (es) 2003-04-25
EP1313716B1 (en) 2007-05-02
PL360744A1 (en) 2004-09-20
HUP0300857A2 (hu) 2003-10-28
PT1313716E (pt) 2007-07-11
CZ2003482A3 (cs) 2003-05-14
CY1107679T1 (el) 2013-04-18
SK1872003A3 (en) 2003-07-01
CA2418104A1 (en) 2002-02-28
BR0113409A (pt) 2003-07-01
ATE361283T1 (de) 2007-05-15
US6930120B2 (en) 2005-08-16
IL154110A0 (en) 2003-07-31
US7345070B2 (en) 2008-03-18
CN1471517A (zh) 2004-01-28
ES2286137T3 (es) 2007-12-01
DE60128239T2 (de) 2008-01-10
KR20030027054A (ko) 2003-04-03
EP1313716A1 (en) 2003-05-28
DE60128239D1 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
IL147821A0 (en) Benzoic acid derivatives and their use as ppar receptor agonists
HUP0201633A3 (en) Alpha-aminosulphonyl-acetohydroxamic acid derivatives with metalloprotease inhibiting effect, preparation and use thereof
PL362917A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
IL154031A0 (en) Substituted sulfonylaminomethylbenzoic acid derivatives and preparation
HUP0300857A3 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
SI1371647T1 (en) Pyridine-3-carboxylic acid derivatives and their use as intermediates
IL155634A0 (en) 3-arylindole derivatives and their use as cb2 receptor agonists
IL149374A0 (en) New use and novel n-azabicyclo-amide derivatives
IL149361A0 (en) Picolinic acid derivatives and their use as fungicides
AU2003206787A8 (en) Sulfonate derivatives and the use therof as latent acids
IL151614A0 (en) Apomorphine derivatives and methods for their use
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
ZA200410054B (en) Propionic acid derivatives and their use as hPPARsactivators.
PL376363A1 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
HUP0302306A3 (en) Propionic acid derivatives with ppar-alpha activating properties
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
AU2001291744A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
SI1259515T1 (en) Thienopyridine derivatives and their use as anti-inflammatory agents
AU2001282268A1 (en) Phenantridine derivatives and their use as anti-telomerase agent
PL355845A1 (en) Substituted isoquinoline derivatives and their use as inticonvulsants
HK1057041A (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU8973201A (en) Biphenyl derivatives and the use thereof as integrin inhibitors
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
GB0017435D0 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees